Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1490 Even Malignant Appendiceal Neuroendocrine Tumors Exhibit No Recurrent Chromosomal Alterations

Introduction: Neuroendocrine tumors (NETs) of the midgut are located in the ileum (iNET), caecum or appendix (aNET). Despite of the similar origin, NETs of the ileum and the appendix behave remarkably different. iNETs show high malignant potential, which manifests with early lymph node or liver metastases. Genetically, the loss of chromosome 18 (Ch18) in 60-74% of cases is the most frequent alteration in iNETs. aNETs are often incidental findings, rarely show metastases, and no chromosomal alterations are known.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Sipos B

Authors: Nann D, Nieser M, Sperveslage J, Henopp T, Vokuhl C,

Keywords: NET,

#1409 A Descriptive Cross-sectional Study of Pain in Patients with Neuroendocrine Tumors

Introduction: Pain is a feared symptom in cancer patients and is reported in 30% of patients during treatment and in 70-90% with advanced disease.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Dam G

Authors: Dam G, Madsen M, Finnerup N, Grønbæk H,

Keywords: Pain, screening, neuropathic pain,

#411 Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Introduction: Peptide receptor radionuclide therapy with 177Lu-DOTATATE (177Lu-PRRT) has shown activity against advanced well-differentiated pancreatic neuroendocrine tumors (P-NET) in previous phase I/II studies.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O,

Keywords: neuroendocrine, peptide receptor radionuclide therapy,

#311 Treatment and Prognosis of Patients with Poorly Differentiated Neuroendocrine Tumors

Introduction: Poorly differentiated neuroendocrine tumors (PDEC) represent less than 10% of all neuroendocrine tumors but have a poor prognosis.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Holt N, Villadsen G, Olesen R, Grønbæk H,

Keywords: poorly differentiated neuroendocrine tumors, PDEC, survival,

#308 Goblet Cell Carcinoid Tumors - A Retrospective Study of Clinical Presentation and Survival

Introduction: Goblet cell carcinoids (GCC) are rare mixed tumors, with partial neuroendocrine differentiation and intestinal-type goblet cell morphology. They usually have a highly malignant potential.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Holt N, Villadsen G, Krogh K, Olesen R, Grønbøk H,

Keywords: Goblet cell carcinoid, survival, prognosis,